Professor, Internal Medicine, Ohio State University College of Medicine
Hematology
Dr. Guido Marcucci, MD
|
|
Give Review
Guido Marcucci, MD practices Hematology. Guido Marcucci has written publications. He has 73 publications published with PubMed. The lastest publication is: 'Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts.' He is registered with Medicare and accepts Medicare payments.
Publications
- Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse Leukemia.
- Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) Acute lymphoblastic leukemia (ALL...
- Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in Acute myeloid leukemia.
- Strategies to inhibit alloantibody production in alloprimed murine recipients of hematopoietic stem cell grafts.
- Promoter-specific hypomethylation is associated with overexpression of PLS3, GATA6 and TWIST1 in Sezary syndrome.
- Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in Acute myeloid leukemia.
- A genome-wide association study of susceptibility to Acute lymphoblastic leukemia in adolescents and young adults.
- miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
- Expression and prognostic impact of lncRNAs in Acute myeloid leukemia.
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary Acute myeloid leukemia.
- Preclinical evaluation of Echinomycin: therapeutic efficacy in relapsed Acute myeloid leukemia without adverse effects on host hematopoietic stem cells.
- Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
- Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers.
- Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML.
- Prognostic gene mutations and distinct gene- and microRNA-expression signatures in Acute myeloid leukemia witha sole trisomy 8.
- NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
- Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia.
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
- Recombinant interleukin-2 in patients aged younger than 60 years with Acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.
- Detection of Extracellular RNAs in Cancer and Viral Infection via Tethered Cationic Lipoplex Nanoparticles Containing Molecular Beacons.
- Eradicating Acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease.
- Acute Myeloid Leukemia, Version 2.2013.
- Arginase-mediated "field" defects in AML.
- Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ Leukemias.
- Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients.
- Patients with chronic lymphocytic Leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab cons...
- Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.
- Towards personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
- In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
- Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status.
- Targeted Delivery of microRNA-29b by Transferrin Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia.
- Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative S...
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Ac...
- Low dose decitabine in very high risk relapsed or refractory Acute myeloid leukaemia in children and young adults.
- Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replica...
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human Acute myeloid leukemia: implications for Axl as a po...
- Dose intensification of daunorubicin and cytarabine during treatment of adult Acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
- New recurrent balanced translocations in Acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461.
- miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
- Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carrier for Therapeutic Delivery in CD74+ B-Cell Malignancies.
- Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in Acute myeloid leukemia cells.
- Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in Acute myeloid leukemia.
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid L...
- Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic Leukemia.
- inv(16)/t(16;16) Acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
- Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation.
- Potential of microRNAs for cancer diagnostics, prognostication and therapy.
- Methods for high-throughput MethylCap-Seq data analysis.
- Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in Acute myeloid leukemia.
- Molecular prognostic factors in cytogenetically normal Acute myeloid leukemia.
- Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia.
- Genome-wide methylation profiling in decitabine-treated patients with Acute myeloid leukemia.
- RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA E...
- The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal Acute myeloid leukemia.
- Pre-clinical activity of a novel CRM1 inhibitor in Acute myeloid leukemia.
- Mll-partial tandem duplication and Flt3-internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human Acute myeloid leukemias.
- Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity.
- miR-3151 interplays with its host gene BAALC and independently impacts on outcome of patients with cytogenetically normal Acute myeloid leukemia.
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine in Acute myeloid leukemia.
- Heritable polymorphism predisposes to high BAALC expression in Acute myeloid leukemia.
- Regulation of Acute graft-versus-host disease by microRNA-155.
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in Acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
- TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte Leukemia.
- Single-agent lenalidomide induces complete remission of Acute myeloid leukemia in patients with isolated trisomy 13.
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic Leukemia c...
- Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal Acute myeloid leukemia with high-ris...
- Identification of medium-sized copy number alterations in whole-genome sequencing.
- Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway.
- Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts.
Schools
Universita Cattolica Del Sacro Cuore
Millard Fillmore Hospital SUNY Buffalo
Catheterization University Sacred Heart
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
Ohio State University Hospital -
University at Buffalo -
University of Cattolica del Sacro Cuore
Hospital
-
Ohio State University Wexner Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1689689127 |
| Last Name Of The Provider | MARCUCCI |
| First Name Of The Provider | GUIDO |
| View All |
Similar Doctors
|
Dr. Pierluigi Porcu, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas M. Davis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nseobong I. Ntukidem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark L. Segal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin M. Bertino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Goldberg, MD |
|
|
Dr. Jonathon B. Cohen, MD |
|
|
Dr. Jerry W. Mitchell Jr., MD |
|
Dr. Michael R. Grever, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Andrew V. Grainger, MD
This Doctor is OpenDoctor Recommended.
|